BMO Capital Maintains Rating, PT on Ionis Pharmaceuticals (IONS) Despite Lower Spinraza Sales
Tweet Send to a Friend
BMO Capital analyst Do Kim reiterated an Outperform rating and $86.00 price target on Ionis Pharmaceuticals (NASDAQ: IONS) despite lower-than-expected ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
